Initiated bioequivalence registration study with Sumatriptan Alginate Film
FOURTH QUARTER 2020 (OCTOBER-DECEMBER)
Net sales amounted to 0.0 MSEK (0.1 MSEK)
R&D costs for the period amounted to 17.6 MSEK (9.7 MSEK)
Profit after tax amounted to -17.0 MSEK (-5.3 MSEK)
Earnings per share for the quarter amounted to -0.34 SEK (-0.17 SEK)
Cash flow from operating activities amounted to -10.1 MSEK (-5.7 MSEK)
Cash and cash equivalents on the balance day amounted to 31.3 MSEK (2.9 MSEK)
Shareholder's equity per December 31, amounted to 109.6 MSEK (82.1 MSEK)∞ At an extraordinary general meeting on November 2, the board decided to issue 3,581,871 shares to an international consortium at a share price of 6.84 SEK, which provided the company with 29 MSEK in additional capital. After the decision ofthe share issue, the number of shares in the company amounts to 51,808,279 and the share capital amounts to 863,471.32 SEK.
THE PERIOD JANUARY-DECEMBER 2020
Net sales amounted to 0.0 MSEK (4.2 MSEK)
R&D costs for the period amounted to 48.4 MSEK (24.2 MSEK)
Profit after tax amounted to -51.4 MSEK (-22.5 MSEK)
Earnings per share for the quarter amounted to -1.19 SEK (-0.72 SEK)∞ Cash flow from operating activities amounted to -35.3 MSEK (-14.8 MSEK)∞ On February 24, 2020, the merger between Karessa Pharma Holding AB (publ) and Klaria Pharma Holding AB (publ), that received approval at extraordinary general meetings in the two companies, was completed. The merger was registered atBolagsverket as of March 6, 2020, and Karessa is thereby dissolved. The terms for the merger was that one share in Karessa was exchanged for 0.6032 new shares in Klaria. In connection with the merger, 6,635,200 new shares in Klaria were issuedto Karessa's shareholders. After the merger has been completed, the number of shares in Klaria amounts to 38,728,448.
In April, the company raised 17.1 MSEK through a directed issue of 5,697,960 shares at a price of 3 SEK per share.
In July, the company raised 11.4 MSEK through a directed issue of 3,800,000 shares at a price of 3 SEK per share.
At an extraordinary general meeting on November 2, the board decided to issue 3,581,871 shares to an internationalconsortium at a share price of 6.84 SEK, which provided the company with 29 MSEK in additional capital. After the decision of the share issue, the number of shares in the company amounts to 51,808,279 and the share capital amounts to 863,471.32 SEK.
Attachments
Original document
Permalink
Disclaimer
Klaria Pharma Holding AB published this content on 29 January 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 January 2021 07:33:01 UTC.
Klaria Pharma Holding AB (publ) is a Sweden-based holding company engaged in the biotechnology and medical research industry. Through its group subsidiaries, the Company is active in developing and commercializing therapeutic drugs and treatment methods in the fields of migraine and pain related to cancer based on a patented drug delivery platform in the form of an alginate-based polymer film, which facilitates rapid and reliable transmucosal absorption via a muco-adhesive film. The Company operates Klaria Pharma AB as a wholly owned subsidiary.